- Home
- MITT vs DTIL Comparison
MITT vs DTIL Comparison
Compare MITT & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITT | DTIL |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.5M | 197.9M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MITT | DTIL |
|---|---|---|
| Price | $5.74 | $6.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $9.00 | ★ $29.40 |
| AVG Volume (30 Days) | ★ 322.8K | 219.8K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.22 | N/A |
| P/E Ratio | $583.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.79 | $3.53 |
| 52 Week High | $9.27 | $9.62 |
Technical Indicators
Market Signals| Indicator | MITT | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 21.42 | 35.77 |
| Support Level | N/A | $6.02 |
| Resistance Level | $8.00 | $7.65 |
| Average True Range (ATR) | 0.14 | 0.39 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 2.75 | 19.81 |
Price Performance
Historical ComparisonAbout MITT AG Mortgage Investment Trust Inc.
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).